On July 17, 2023, FDA approved nirsevimab-alip for newborns and infants born during or entering their first season of Respiratory Syncytial Virus (RSV), and children up to 24 months during their second RSV season who are vulnerable to severe RSV disease. Nirsevimab-alip—brand name Beyfortus—is a monoclonal antibody (mAB) that is administered as a single intramuscularly injection before or during the RSV season, according to FDA. One dose may prevent RSV during the entire season.
